AI assistant
BIOVENTIX PLC Director's Dealing 2025
7520_mrq_2025-11-04_2b7a85f0-3141-4367-b766-67bc4b775da3.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1720G
BioVentix PLC
04 November 2025
Bioventix plc
("Bioventix" or "the Company")
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company has been notified that earlier today Peter Harrison, Chief Executive Officer, and his wife Abigail Harrison have purchased ordinary shares of 5 pence each in the Company ("Ordinary Shares") at the quantities and prices set out in the table below.
| Director/PDMR | Position | No of shares purchased | Purchase Price |
| Peter Harrison | Chief Executive Officer | 875 | 2,220 pence |
| Abigail Harrison | PCA of Peter Harrison | 875 | 2,220 pence |
Following the Purchase, Peter Harrison, together with his persons closely associated, has a beneficial interest in 304,042 Ordinary Shares, representing approximately 5.8 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
| Bioventix plc Peter Harrison |
Chief Executive Officer | Tel: 01252 728 001 |
| Cavendish Geoff Nash / Elysia Bough Nigel Birks / Harriet Ward |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Peter Harrison |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Bioventix Plc |
| b) | LEI | 213800225MHX7LZQY108 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each |
| Identification code | GB00B4QVDF07 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | 875 Ordinary Shares 2,220 pence |
| d) | Aggregated information: · Aggregated volume · Price |
Single transaction as in 4c) above |
| e) | Date of the transaction | 4 November 2025 |
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Abigail Harrison |
| 2. | Reason for the Notification | |
| a) | Position/status | Wife of and PCA with Peter Harrison, Chief Executive Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Bioventix Plc |
| b) | LEI | 213800225MHX7LZQY108 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each |
| Identification code | GB00B4QVDF07 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | 875 Ordinary Shares 2,220 pence |
| d) | Aggregated information: · Aggregated volume · Price |
Single transaction as in 4c) above |
| e) | Date of the transaction | 4 November 2025 |
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAKFLEENSFFA